Fernando Pardo1, Bruno Sangro2, Rheun-Chuan Lee3, Derek Manas4,5, Rohan Jeyarajah6, Vincent Donckier7, Geert Maleux8, Antonio D Pinna9, Lourens Bester10, David L Morris11, David Iannitti12, Pierce K Chow13, Richard Stubbs14, Paul J Gow15, Gianluca Masi16, Kevin T Fisher17, Wan Y Lau18, Konstantinos Kouladouros19, Georgios Katsanos20, Giorgio Ercolani21, Fernando Rotellar22, José I Bilbao23, Michael Schoen19. 1. HPB and Transplant Surgery, Clinica Universidad de Navarra, IDISNA, Pamplona, Navarra, Spain. fpardo@unav.es. 2. Liver Unit, Clinica Universidad de Navarra, IDISNA, CIBEREHD, Pamplona, Navarra, Spain. 3. Radiology, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan. 4. Institute of Transplantation, University of Newcastle Upon Tyne, Newcastle Upon Tyne, UK. 5. Newcastle NHS Trust, Newcastle Upon Tyne, UK. 6. Surgical Oncology, Methodist Dallas Medical Center, Dallas, TX, USA. 7. Department of Surgery, Institut Jules Bordet, Université Libre de Bruxelles and Centre de Chirurgie Hépato-Biliaire de l'ULB, Brussels, Belgium. 8. Radiology, University Hospitals Leuven, Louvain, Belgium. 9. Hepatobiliary and Transplant Surgery, S. Orsola-Malpighi, University of Bologna, Bologna, Italy. 10. Interventional Radiology, St Vincent's Hospital, Sydney, NSW, Australia. 11. Department of Surgery, St George Hospital, University of New South Wales, Kogarah, NSW, Australia. 12. HPB Surgery, Carolinas Medical Center, Charlotte, NC, USA. 13. Surgical Oncology, National Cancer Center, Singapore, Singapore. 14. Hepatobiliary Surgery, Wakefield Clinic, Wellington, New Zealand. 15. Transplant Hepatology, Austin Hospital, Heidelberg, VIC, Australia. 16. Medical Oncology, Ospedale Santa Chiara, Pisa, Italy. 17. Department of Surgery, Saint Francis Hospital, Tulsa, OK, USA. 18. Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, Hong Kong. 19. Klinikum Karlsruhe, Karlsruhe, Germany. 20. Department of Abdominal Surgery, Hôpital Erasme, Université Libre de Bruxelles and Centre de Chirurgie Hépato-Biliaire de l'ULB, Brussels, Belgium. 21. Hepatobiliary and Transplant Surgery, Sant'Orsola Hospital, University of Bologna, Bologna, Italy. 22. HPB and Transplant Surgery, Clinica Universidad de Navarra, IDISNA, Pamplona, Navarra, Spain. 23. Interventional Radiology, Clinica Universidad de Navarra, IDISNA, Pamplona, Navarra, Spain.
Abstract
BACKGROUND: Reports show that selective internal radiation therapy (SIRT) may downsize inoperable liver tumors to resection or transplantation, or enable a bridge-to-transplant. A small-cohort study found that long-term survival in patients undergoing resection following SIRT appears possible but no robust studies on postsurgical safety outcomes exist. The Post-SIR-Spheres Surgery Study was an international, multicenter, retrospective study to assess safety outcomes of liver resection or transplantation following SIRT with yttrium-90 (Y-90) resin microspheres (SIR-Spheres®; Sirtex). METHODS: Data were captured retrospectively at participating SIRT centers, with Y-90 resin microspheres, surgery (resection or transplantation), and follow-up for all eligible patients. Primary endpoints were perioperative and 90-day postoperative morbidity and mortality. Standard statistical methods were used. RESULTS: The study included 100 patients [hepatocellular carcinoma: 49; metastatic colorectal cancer (mCRC): 30; cholangiocarcinoma, metastatic neuroendocrine tumor, other: 7 each]; 36% of patients had one or more lines of chemotherapy pre-SIRT. Sixty-three percent of patients had comorbidities, including hypertension (44%), diabetes (26%), and cardiopathy (16%). Post-SIRT, 71 patients were resected and 29 received a liver transplant. Grade 3+ peri/postoperative complications and any grade of liver failure were experienced by 24 and 7% of patients, respectively. Four patients died <90 days postsurgery; all were trisectionectomies (mCRC: 3; cholangiocarcinoma: 1) and typically had one or more previous chemotherapy lines and presurgical comorbidities. CONCLUSIONS: In 100 patients undergoing liver surgery after receiving SIRT, mortality and complication rates appeared acceptable given the risk profile of the recruited patients.
BACKGROUND: Reports show that selective internal radiation therapy (SIRT) may downsize inoperable liver tumors to resection or transplantation, or enable a bridge-to-transplant. A small-cohort study found that long-term survival in patients undergoing resection following SIRT appears possible but no robust studies on postsurgical safety outcomes exist. The Post-SIR-Spheres Surgery Study was an international, multicenter, retrospective study to assess safety outcomes of liver resection or transplantation following SIRT with yttrium-90 (Y-90) resin microspheres (SIR-Spheres®; Sirtex). METHODS: Data were captured retrospectively at participating SIRT centers, with Y-90 resin microspheres, surgery (resection or transplantation), and follow-up for all eligible patients. Primary endpoints were perioperative and 90-day postoperative morbidity and mortality. Standard statistical methods were used. RESULTS: The study included 100 patients [hepatocellular carcinoma: 49; metastatic colorectal cancer (mCRC): 30; cholangiocarcinoma, metastatic neuroendocrine tumor, other: 7 each]; 36% of patients had one or more lines of chemotherapy pre-SIRT. Sixty-three percent of patients had comorbidities, including hypertension (44%), diabetes (26%), and cardiopathy (16%). Post-SIRT, 71 patients were resected and 29 received a liver transplant. Grade 3+ peri/postoperative complications and any grade of liver failure were experienced by 24 and 7% of patients, respectively. Four patients died <90 days postsurgery; all were trisectionectomies (mCRC: 3; cholangiocarcinoma: 1) and typically had one or more previous chemotherapy lines and presurgical comorbidities. CONCLUSIONS: In 100 patients undergoing liver surgery after receiving SIRT, mortality and complication rates appeared acceptable given the risk profile of the recruited patients.
Authors: Cathal O'Leary; Megan Greally; John McCaffrey; Peter Hughes; Leo L P Lawler; Martin O'Connell; Tony Geoghegan; Cormac Farrelly Journal: Ir J Med Sci Date: 2018-03-06 Impact factor: 1.568
Authors: D Rohan Jeyarajah; Maria B Majella Doyle; N Joseph Espat; Paul D Hansen; David A Iannitti; Joseph Kim; Thavam Thambi-Pillai; Brendan C Visser Journal: J Gastrointest Oncol Date: 2020-04
Authors: I Kurilova; V Pompa; R Guerrero; Mesa A Tapias; Mizrrahi D Calatayud; C Fondevila; J A González; J Duch; F M Gomez Journal: Cardiovasc Intervent Radiol Date: 2020-06-08 Impact factor: 2.740
Authors: Andrew Kennedy; Daniel B Brown; Jonas Feilchenfeldt; John Marshall; Harpreet Wasan; Marwan Fakih; Peter Gibbs; Alexander Knuth; Bruno Sangro; Michael C Soulen; Gianfranco Pittari; Ricky A Sharma Journal: J Gastrointest Oncol Date: 2017-12
Authors: Florian Bösch; Harun Ilhan; Vanessa Pfahler; Michael Thomas; Thomas Knösel; Valentin Eibl; Sebastian Pratschke; Peter Bartenstein; Max Seidensticker; Christoph J Auernhammer; Christine Spitzweg; Markus O Guba; Jens Werner; Martin K Angele Journal: Hepatobiliary Surg Nutr Date: 2020-06 Impact factor: 7.293
Authors: Christopher Noda; Gregory A Williams; Gretchen Foltz; Hyun Kim; Dominic E Sanford; Chet W Hammill; Ryan C Fields Journal: J Surg Oncol Date: 2020-07-13 Impact factor: 2.885
Authors: Mohammad Elsayed; Mohammad Loya; James Galt; David M Schuster; Zachary L Bercu; Janice Newsome; David Brandon; Sonia Benenati; Keywan Behbahani; Richard Duszak; Ila Sethi; Nima Kokabi Journal: World J Gastrointest Oncol Date: 2021-05-15